This Week in NEJM | GenomeWeb

This Week in NEJM


In NEJM this week, a team of German researchers report a study of neoadjuvant chemotherapy combined with bevacizumab for the treatment of HER2-negative breast cancer. The team randomly assigned 1,948 patients to receive neoadjuvant epirubicin and cyclophosphamide followed by docetaxel, either with or without concomitant bevacizumab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.